维百奥现货销售Svar Lifescience现货试剂盒

| 产品信息

品名：Svar Lifescience现货试剂盒

品牌：Lifecore

| 产品系列

1）WIESLAB® Complement Alternative Pathway (RUO)

货号：COMPLAP330RUO

The Wieslab® Complement System Alternative Pathway kit is an enzyme immunoassay for the qualitative determination of functional alternative complement pathway and determination of complement deficiencies in human serum. Non-human primate and swine samples can also be assayed with Wieslab® Complement System Alternative pathway.

The Wieslab Complement assay combines tthe specific activation of the pathway with the use of labeled antibodies specific for a neoepitope of the terminal complement complex, C5b-9, produced as the result of complement activation. The amount of C5b-9 generated is proportional to the functional activity of the complement system. The convenient ELISA technology has several advantages compared to the traditional hemolytic assays.

2）WIESLAB® Complement MBL Pathway (RUO)

货号：COMPLMP320RUO

The Wieslab® Complement System MBL pathway kit is an enzyme immunoassay for the qualitative determination of MBL complement pathway and determination of complement deficiencies in human serum. Non-human primate and swine samples can also be assayed with Wieslab Complement System MBL Pathway.

The assay combines the specific activation of each pathway with the use of labeled antibodies specific for a neoepitope of the terminal complement complex, C5b-9, produced as a result of complement activation. The amount of C5b-9 generated is proportional to  the functional activity of complement pathways.

3）WIESLAB® Complement Classical Pathway (RUO)

货号：COMPLCP310RUO

The Wieslab® Complement System Classical Pathway is an enzyme immunoassay for the qualitative and/or semi-quantitative determination of functional classical complement pathway and determination of complement deficiencies in human serum. Non-human primate and swine samples can also be assayed with Wieslab® Complement System Classical Pathway.

The Wieslab Complement System Classical Pathway assay combines the specific activation of the pathway with the use of labeled antibodies specific for a neoepitope of the terminal complement complex, C5b-9, produced as the result of complement activation. The amount of complement activation can be expressed either in a qualitative way relative the value of a positive control or in a semi-quantitative way using a calibrator curve derived from a separate lyophilized activity control.